摘要
【目的】探讨甲磺酸阿帕替尼治疗晚期卵巢癌的疗效及对血清人附睾蛋白4(HE4)、糖类抗原125(CA125)、激肽释放酶10(hK10)水平的影响。【方法】94例晚期卵巢癌患者,其中47例采用紫杉醇、卡铂为基础的化疗方案进行治疗(对照组),另外47例在对照组基础上给予甲磺酸阿帕替尼治疗(观察组)。对比两组的近期疗效、3年生存率及生存时间,化疗前后血清HE4、CA125、hK10的水平变化。【结果】化疗后,观察组患者的总有效率为66.67%(30/45),高于对照组的45.65%(21/46),且差异具有统计学意义(P<0.05)。化疗前,两组患者的血清CA125、HE4、hK10水平比较,差异均无统计学意义(P>0.05);化疗后,观察组的血清CA125、HE4、hK10水平均低于对照组,且差异具有统计学意义(P<0.05)。随访3年,观察组的3年累计生存率为44.44%(20/45),高于对照组的32.61%(15/46)(P<0.05);观察组的总生存时间为35.00个月,长于对照组的28.00个月(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】在常规方案的基础上加用甲磺酸阿帕替尼治疗有利于降低晚期卵巢癌患者血清CA125、HE4、hK10水平,能提高患者近期化疗效果及改善远期预后。
【Objective】To investigate the efficacy of apatinib mesylate in the treatment of advanced ovarian cancer.【Methods】A total of 94 patients with advanced ovarian cancer were treated with chemotherapy based on paclitaxel and carboplatin(control group),and 47 patients were treated with apatinib mesylate(observation group).The short-term efficacy,3-year survival rate and survival time of the two groups were compared.The changes of serum human epididymal protein 4(HE4),carbohydrate antigen 125(CA125)and kallikrein 10(hK10)levels before and after chemotherapy were compared.【Results】After chemotherapy,the total effective rate in the observation group was 66.67%(30/45),higher than 45.65%(21/46)in the control group,and the difference was statistically significant(P<0.05).Before chemotherapy,there was no significant difference in serum CA125,HE4 and hK10 levels between the two groups(P>0.05);After chemotherapy,the levels of serum CA125,HE4 and hK10 in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).The 3-year cumulative survival rate in the observation group was 44.44%(20/45),which was higher than 32.61%(15/46)in the control group(P<0.05);The overall survival time of the observation group was 35.00 months,which was longer than that of the control group(28.00 months)(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).【Conclusion】On the basis of routine regimen,the addition of apatinib mesylate can reduce the serum levels of CA125,HE4 and hK10 in patients with advanced ovarian cancer,and improve the short-term chemotherapy effect and long-term prognosis.
作者
董飞天
李瑞宁
DONG Fei-tian;LI Rui-ning(Radiation Oncology,Ankang People's Hospital,Ankang Shaanxi 725000)
出处
《医学临床研究》
CAS
2022年第7期1054-1057,共4页
Journal of Clinical Research
